The OSMA Division of Regulatory Affairs actively monitors the activities of state and federal regulatory agencies. If necessary, the OSMA engages with the agency and/or submits comments to the agency that is drafting new or amended rules. Advocating the OSMA’s position on draft rules is one of the most active points of involvement in the entire regulatory process.
For more information, contact Jennifer Hayhurst
, OSMA Director of Regulatory Affairs, (614) 527-6762.
OSMA Rule Watch
The OSMA is actively monitoring the following rules:
State Medical Board of Ohio
The rule number is a link to the rule and a memo explaining the proposed action.
Ohio State Board of Pharmacy
- Compounding Rules Update! (7-21-16)
Due to recent feedback regarding the prescriber compounding rules, the pharmacy board has retracted and redrafted OAC 4729-16-04, the dangerous drugs compounding rule, and is advising previously exempt prescriber practices to refrain from application to the Board as a Terminal Distributor of Dangerous Drugs until April 1, 2017. Please note: The extension does not apply to prescribers who compound hazardous drugs. The new hazardous drug compounding rule (4729-16-11) will be implemented and enforced.
Guidance & Updated Resolution: Terminal Distributor’s License for Prescribers Compounding Dangerous Drugs
Ohio Administrative Code 4729-16-11 Hazardous drugs compounded by a prescriber
Ohio Bureau of Workers' Compensation